Clin Mol Hepatol.
2020 Jul;26(3):309-311. 10.3350/cmh.2020.0061.
Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
- Affiliations
-
- 1Department of Radiology, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2504504
- DOI: http://doi.org/10.3350/cmh.2020.0061
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria
- Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines
- Noninvasive diagnostic criteria for hepatocellular carcinoma
- Validation of the Korean Liver Cancer Association-National Cancer Center 2018 Criteria for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using Magnetic Resonance Imaging
- Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology
